Skip to content
MarketScale
‹ Back to IndustriesSciences

The Life of a Scope

Sam Harrison, a Senior Clinical Educator at Censis Technologies, discussed the lifecycle of a scope and how Censis's tools, ScopeTrac and CensiTrac, are essential. The tools aid in the deamination, cleaning, disinfecting, and storage tracking processes, and ensure compliance with regulations.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from Censis on MarketScale.

By Sciences · CensitracEndoscope ReprocessorScope TechnologyScopes
Share

Key takeaways

01

Scopes go through deamination before entering the OR.

02

CensiTrac tracks and documents cleaning and reprocessing procedures.

03

ScopeTrac helps comply with regulatory requirements and enhance tracking capabilities.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Sam Harrison, Senior Clinical Educator at Censis Technologies, provided Tyler Kern with an education in endoscopy when he guided him through the lifecycle of a scope and how Censis technologies’ ScopeTrac and CensiTrac play a vital role in the process.

Scopes first go through a deamination process before they enter the OR. CensiTrac then captures the cleaning and reprocessing procedures.

“When the tech checks that scope into the scope processing module, the instructions for use are displayed,” Harrison said. “Those instructions for use can be customized per the scope model, the manufacturer’s IFUs can be uploaded, or video can be uploaded to make it as easy as possible for the end-user.”

After the scope receives reprocessing, it goes to a cleaning room for disinfecting. This process requires tracking, which CensiTrac streamlines. Once disinfected and logged, a scope will go to a clean storage area, and CensiTrac will provide information on those scope’s storage location.

Once a scope enters the procedure room, CensiTrac’s case-tracking module can associate that scope to a patient through a case ID#. “In each area, CensiTrac is used to track and document every required process,” Harrison said.

ScopeTrac is another critical piece of the digital scope record process that makes it easy to comply with regulations.

“Having those processing steps there to help abide by the regulatory requirements is huge,” Harrison said. And, with the added functionality of video and image uploads, techs have additional tools and resources at their disposal to correctly identify and log in scopes.

While ScopeTrac with CensiTrac addresses all these needs, Harrison mentioned that there is now ScopeTrac Advanced, which provides additional solutions, such as OR scheduler interface capabilities.

Interested in learning more about Censis Technologies’ surgical asset management platform? Visit Censis.com.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Censis

Part of this channel

Censis

Surgical instrument management software for over 1,300 U.S. hospitals.

Visit the channel

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers has terminated its agreement with Cellares, which raises concerns about the standardized capacity for cell therapy production. This decision highlights the importance of aligning manufacturing processes with production capabilities, rather than merely focusing on the availability of factory slots.

  • 01Bristol Myers has terminated its agreement with Cellares, affecting cell therapy capacity.
  • 02Aligning process fit with production capabilities is crucial for cell therapy success.
  • 03Factory slots alone are not sufficient to ensure supply plans in cell therapy production.

Aug 26, 2026

Argonne’s AI agents push materials R&D toward days-long cycles

Argonne’s AI agents push materials R&D toward days-long cycles

Argonne National Laboratory is utilizing AI agents to accelerate materials R&D cycles, reducing the time span to just a few days. This advancement hinges on prioritizing dataflow and security over larger AI models. The novel approach aims to streamline processes and enhance the efficiency of research and development activities.

  • 01Argonne National Laboratory is using AI agents to significantly shorten materials R&D cycles.
  • 02The focus of procurement has shifted to dataflow and security rather than larger AI models.
  • 03Improved workflows facilitate more efficient research and development efforts.

Aug 25, 2026

Cancer diagnostics growth is forcing labs to budget for data, not just instruments

Cancer diagnostics growth is forcing labs to budget for data, not just instruments

The growth in cancer diagnostics is prompting laboratories to allocate budgets not only for instruments but also for data management. Market forecasts predict an increase in the cancer diagnostics market from $29.86 billion in 2026 to $44.92 billion by 2031. Staffing is identified as a significant operational constraint according to industry insights.

  • 01Cancer diagnostics market is expected to grow from $29.86 billion in 2026 to $44.92 billion by 2031.
  • 02Laboratories are increasingly required to budget for data management alongside instruments.
  • 03Staffing is a major operational constraint in the growth of cancer diagnostics.

Aug 24, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

Senior Clinical Educator at Censis Technologies

Sam Harrison guides the education in endoscopy and the lifecycle of scopes at Censis Technologies. He explains how ScopeTrac and CensiTrac play vital roles in the process. He ensures compliance with regulatory requirements and streamlines the processes from cleaning to patient tracking.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512